Sightful Invest
  • Business
  • Investing
  • Politics
  • Stock
Top Posts
House conservatives to lead prayer for end to...
GOP senators push for Charlie Kirk statue in...
Biden autopen investigation ‘has heated up’ as DOJ...
States sue Trump admin over billions in looming...
NASA’s ‘quiet’ supersonic jet completes first flight in...
Trump claims Asia tour returned ‘trillions’ to US...
‘Unprecedented’ panel of federal judges will tackle antisemitism...
Schumer, Dems call ‘bull—-‘ on Trump administration over...
US rescue teams to descend on hard-hit Caribbean...
Republicans dub Fetterman ‘voice of reason’ after he...
  • Business
  • Investing
  • Politics
  • Stock

Sightful Invest

Investing

Cardiex September 2024 Quarter Update

by admin October 31, 2024
October 31, 2024
Cardiex September 2024 Quarter Update

Cardiex Limited (ASX:CDX) (the “Company”) is pleased to report its activities during the September quarter 2024.

Highlights:

  • Manufacturing of the initial 8,000 CONNEQT Pulse units commenced with the expected arrival of units in the USA late-November/early December.
  • Pulse waitlist now exceeds 20,000 with activities now focused on sales conversion.
  • Completed clinical validation study of wearable technology, with an FDA pre-submission meeting scheduled for November to advance the clearance process.
  • Completion of usability study for submission for additional OTC clearance for the Pulse.
  • Strong clinical sales pipeline with momentum towards new Q2 contracts.
  • Grand prize winner of the U.S. National Institute of Health’s RADx® Maternal Health Challenge securing US$525,000 in prize funding.
  • New R&D Term Loan Facility with Mitchell Asset Management to provide additional flexibility with R&D initiatives and working capital requirements.

Click here for the September Quarterly Appendix 4C

Click here for the full ASX Release

This post appeared first on investingnews.com

previous post
WGC: Gold Demand Hits Q3 Record as Western ETF Investors Return
next post
Emyria and UWA in Partnership to Commercialise Novel Serotonin-Releasing Agents for Mental Health and Neurology

You may also like

Grant Williams: Market Turbulence Ahead, but Resource Space...

January 30, 2025

Maria Smirnova: Gold, Silver Price Drivers Still in...

February 4, 2025

Metals Exploration Eyes Condor Gold, Calibre Mining Denies...

December 3, 2024

What is De-Dollarization and is it Good or...

February 4, 2025

Anteros Secures Knob Lake Property Mineral Tenure to...

February 5, 2025

Silver Price Surges Above US$48, Approaches All-time High

October 3, 2025

Brunswick Exploration Has Now Identified Four Major New...

July 9, 2025

6 Mining Companies Make Top 20 on 2025...

January 18, 2025

Panelists: Gold “Essential” to Own as Volatility Rises...

February 11, 2025

Jeff Clark: Gold Bull Market Running, These Stocks...

July 19, 2025

Recent Posts

  • House conservatives to lead prayer for end to political violence, government shutdown
  • GOP senators push for Charlie Kirk statue in Trump’s National Garden of American Heroes
  • Biden autopen investigation ‘has heated up’ as DOJ looks at Delaware, DC: source
  • States sue Trump admin over billions in looming cuts to SNAP, food stamps
  • NASA’s ‘quiet’ supersonic jet completes first flight in potential breakthrough for commercial air travel

    Sign up for our newsletter to receive the latest insights, updates, and exclusive content straight to your inbox! Whether it's industry news, expert advice, or inspiring stories, we bring you valuable information that you won't find anywhere else. Stay connected with us!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (946)
    • Investing (3,304)
    • Politics (4,045)
    • Stock (4)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sightfulinvest.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 Sightful Invest. All Rights Reserved.